Cargando…

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

BACKGROUND: Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile. METHODS: A literature-based meta-analysis to quantify the magn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuppone, Federica, Bria, Emilio, Vaccaro, Vanja, Puglisi, Fabio, Fabi, Alessandra, Sperduti, Isabella, Carlini, Paolo, Milella, Michele, Nisticò, Cecilia, Russillo, Michelangelo, Papaldo, Paola, Ferretti, Gianluigi, Aapro, Matti, Giannarelli, Diana, Cognetti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120715/ https://www.ncbi.nlm.nih.gov/pubmed/21569417 http://dx.doi.org/10.1186/1756-9966-30-54

Ejemplares similares

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2010)

Targeting targeted agents: open issues for clinical trial design
por: Bria, Emilio, et al.
Publicado: (2009)

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
por: Rossi, Valentina, et al.
Publicado: (2019)

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
por: Ferretti, G, et al.
Publicado: (2006)

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
por: Fabi, Alessandra, et al.
Publicado: (2015)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
por: Carbognin, Luisa, et al.
Publicado: (2015)

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center
por: Fabi, Alessandra, et al.
Publicado: (2011)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
por: Fabi, Alessandra, et al.
Publicado: (2009)

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology
por: Bazzichetto, Chiara, et al.
Publicado: (2020)

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
por: Falcone, Italia, et al.
Publicado: (2020)

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
por: Bazzichetto, Chiara, et al.
Publicado: (2020)

BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer
por: Conciatori, Fabiana, et al.
Publicado: (2020)

Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer
por: Bria, Emilio, et al.
Publicado: (2014)

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
por: Falcone, Italia, et al.
Publicado: (2020)

Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement
por: Conciatori, Fabiana, et al.
Publicado: (2019)

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
por: Novelli, Flavia, et al.
Publicado: (2008)

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?
por: Visca, Paolo, et al.
Publicado: (2014)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
por: Stagno, Anna, et al.
Publicado: (2021)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021)

The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey
por: Di Noia, Vincenzo, et al.
Publicado: (2021)

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
por: Garufi, Giovanna, et al.
Publicado: (2023)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy
por: Conciatori, Fabiana, et al.
Publicado: (2020)

The protective side of progesterone
por: Ferretti, Gianluigi, et al.
Publicado: (2007)

mTOR Cross-Talk in Cancer and Potential for Combination Therapy
por: Conciatori, Fabiana, et al.
Publicado: (2018)

Role of mTOR Signaling in Tumor Microenvironment: An Overview
por: Conciatori, Fabiana, et al.
Publicado: (2018)

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
por: Mastrantoni, Luca, et al.
Publicado: (2023)

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
por: Mormando, Marilda, et al.
Publicado: (2020)

PTEN: Multiple Functions in Human Malignant Tumors
por: Milella, Michele, et al.
Publicado: (2015)

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition
por: Conciatori, Fabiana, et al.
Publicado: (2022)

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
por: Lombardi, Pasquale, et al.
Publicado: (2023)

Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers
por: Caruso, Anita, et al.
Publicado: (2009)

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
por: Fabi, Alessandra, et al.
Publicado: (2016)

Palonosetron as an anti-emetic and anti-nausea agent in oncology
por: Aapro, Matti S
Publicado: (2007)

SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly
por: Aapro, Matti
Publicado: (2011)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
por: Aapro, Matti
Publicado: (2018)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
por: Aapro, Matti
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4qj5nvptnujvqdro3s5urfafap